원숭이두창 백신 및 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Monkeypox Vaccine And Treatment Market size is expected to reach USD 304.23 Million in 2034 from USD 121.47 Million (2025) growing at a CAGR of 10.74% during 2026-2034.

The global monkeypox vaccine and treatment market has gained considerable attention due to the increasing incidence of monkeypox infections across various regions. The outbreak of the disease in several countries has highlighted the need for effective vaccines and antiviral treatments. As governments and healthcare organizations focus on controlling outbreaks, the demand for preventive vaccines and therapeutic drugs is increasing steadily.

Pharmaceutical companies and research institutions are investing heavily in vaccine development and antiviral therapies to address the disease. Existing vaccines originally developed for smallpox have shown effectiveness against monkeypox, while new treatments are being explored to improve disease management. Public health initiatives and government procurement programs are also supporting the expansion of the market.

In the future, the monkeypox vaccine and treatment market is expected to grow as global surveillance and preparedness for emerging infectious diseases increase. Rising awareness, improved diagnostic capabilities, and ongoing research into next-generation vaccines will contribute to market development. Continued collaboration between governments, healthcare organizations, and pharmaceutical companies will play a key role in shaping the market's future.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others)
• Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others)
• Vaccinia Immune Globulin (Vig)

By Gender

• Male
• Female
• Others

By Route Of Administration

• Oral
• Injectable
• By-End-Use
• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Bavarian Noric, SIGA Technologies, Chimerix, Emergent, Gilead Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccinia Immune Globulin (Vig) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Gender
• 5.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY BY-END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast By-end-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Gender
  • 8.2.3 By Route Of Administration
  • 8.2.4 By By-end-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Gender
  • 8.3.3 By Route Of Administration
  • 8.3.4 By By-end-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Gender
  • 8.4.3 By Route Of Administration
  • 8.4.4 By By-end-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Gender
  • 8.5.3 By Route Of Administration
  • 8.5.4 By By-end-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Gender
  • 8.6.3 By Route Of Administration
  • 8.6.4 By By-end-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MONKEYPOX VACCINE AND TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bavarian Noric
  • 10.2.2 SIGA Technologies
  • 10.2.3 Chimerix
  • 10.2.4 Emergent
  • 10.2.5 Gilead Sciences Inc